▮ DFV TERMINAL
--:--:-- UTC SIGN IN
F1 Terminal / VRTX

VRTX — VERTEX PHARMACEUTICALS INC / MA

—
Nasdaq · Health Care · Pharmaceuticals · CIK 875320 ·
Last close
$468.42
Market Cap
$118.89B
52W High
$470.82
52W Low
$412.27
ADV30
1,393,824
Next earnings
2026-08-03
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 2,986,900,000 2,594,100,000 1,138,800,000 1,031,400,000 26,484,400,000 5,492,900,000 7,122,500,000
Dec 2025 3,190,000,000 2,724,000,000 1,130,300,000 1,191,100,000 25,643,000,000 5,084,800,000 6,977,200,000
Sep 2025 3,076,400,000 2,661,600,000 1,238,800,000 1,082,900,000 24,862,300,000 4,939,600,000 7,543,500,000
Jun 2025 2,964,700,000 2,557,200,000 1,154,200,000 1,032,900,000 24,036,700,000 4,972,200,000 6,861,300,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$4,240,600,000
Investing CF
$-1,321,500,000
Financing CF
$-2,119,700,000
CapEx
$-530,300,000
Dividends Paid
—
Buybacks
$-2,256,100,000
EPS Diluted TTM
$16.86
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$14,591,400,000
Inventory
$1,766,700,000
Receivables
$1,996,100,000
ST Investments
$1,753,800,000
EBIT TTM
$5,061,900,000
Pretax Income TTM
$5,165,700,000
Interest Exp TTM
$10,300,000
Analysts
28

Yahoo Snapshot (yfinance, live)

Total Revenue
$12,218,000,384
EBITDA
$4,981,199,872
Free Cash Flow
$2,783,225,088
Enterprise Value
$113,627,332,608
Total Cash
$7,246,700,032
Total Debt
$1,986,499,968
Shares Out
253,805,417
Trailing EPS
$16.86
Book Value
$76.18
ROE
24.2%
ROA
12.1%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 12,001,300,000 4,554,400,000 3,953,200,000 25,643,000,000 6,977,200,000 — 3,631,400,000
Dec 2024 11,020,100,000 -233,400,000 -535,600,000 22,533,200,000 6,123,600,000 — -492,600,000
Dec 2023 9,869,200,000 3,780,400,000 3,619,600,000 22,730,200,000 5,149,800,000 — 3,537,300,000
Dec 2022 8,930,700,000 4,249,900,000 3,322,000,000 18,150,900,000 4,238,200,000 — 4,129,900,000

TTM Snapshot

Revenues TTM
$9,573,800,000
NetIncome TTM
$3,863,100,000
OpCashFlow TTM
$0
Assets (Latest)
$22,533,200,000
Forward EPS
$21.47

Max Pain — expiry 2026-07-17

max pain strike: $460.00 · spot: $475.20 · call oi: 3,814 · put oi: 3,204
Expected Move to 2026-07-17: ±$24.15 (5.08%) — implied range $451.05 – $499.35 · ATM straddle on $480.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
BMY BRISTOL MYERS SQUIBB CO $113.40B $55.53 —
GSK GSK plc $104.31B $52.07 —
GLAXF GSK plc $102.97B $25.70 —
PFE PFIZER INC $140.89B $24.72 —
SNYNF Sanofi $99.81B $83.39 —

News headlines (Yahoo Finance, 1h cache)

Vertex Energy Announces 6,000 bpd Group III Base Oil Expansion Project
2026-06-24 14:00 · Yahoo
The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch.
2026-06-23 15:50 · Yahoo
Vertex Pharmaceuticals (VRTX) Stock After Strong Multi‑Year Run Is The Price Still Reasonable
2026-06-23 13:12 · Yahoo
Positive Pediatric CASGEVY Data Might Change The Case For Investing In Vertex Pharmaceuticals (VRTX)
2026-06-23 12:08 · Yahoo
2 Reasons to Like VRTX (and 1 Not So Much)
2026-06-22 17:55 · Yahoo
3 of Wall Street’s Favorite Stocks to Consider Right Now
2026-06-22 12:51 · Yahoo
Vertex Has a Head Start in Non-Opioid Pain. Eli Lilly Just Spent Billions to Catch Up. Here's What That Means for Both Stocks.
2026-06-20 06:20 · Yahoo
Can Vertex's Kidney Pipeline Power Its Next Growth Phase?
2026-06-19 12:14 · Yahoo
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's Why
2026-06-18 21:50 · Yahoo
3 Market-Beating Stocks Worth Investigating
2026-06-18 13:33 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.
SEC EDGAR filings → · StockAnalysis.com → · OpenInsider →